Enan­ta sells off over 50% of roy­al­ty pay­ments from Mavyret in ex­change for $200M

Enan­ta Phar­ma­ceu­ti­cals is sell­ing off roy­al­ty pay­ments from its Ab­b­Vie-part­nered drug Mavyret, its biggest rev­enue dri­ver, to a Cana­di­an pen­sion plan for $200 mil­lion.

Enan­ta has sold 54.5% of its fu­ture world­wide Mavyret roy­al­ty pay­ments from Ab­b­Vie to OMERS, a Cana­di­an de­fined ben­e­fit pen­sion plan, in ex­change for $200 mil­lion be­gin­ning in Ju­ly 2023 un­til June 2032. The roy­al­ty pay­ments are based on net sales of Mavyret dur­ing that time pe­ri­od, with to­tal pay­ments capped at 1.42 times the pur­chase price, or $284 mil­lion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER